Evaluation of C-Reactive Protein in Patients with Chronic Obstructive Pulmonary Disease
DOI:
https://doi.org/10.3889/oamjms.2015.061Keywords:
C-reactive protein, COPD, bronchial obstruction, co-morbidites, proinflammatory cytokinesAbstract
BACKGROUND: Chronic Obstructive Pulmonary Disease (COPD) is associated with evidence of systemic oxidative stress, activation of circulating inflammatory cells and increased plasma level of proinflamatory cytokines which include C-reactive protein (CRP). CRP is one biomarker of extrapulmonary or systemic consequences of COPD that can be detected.
AIM: The aim of this research is to determine whether the level of CRP statistically significantly correlates with the level of bronchial obstruction and the accompanying co-morbidities in patients with COPD.
MATERIAL AND METHODS: This study included 80 patients with exacerbation of COPD, hospitalised at the Institute for Lung Diseases and Tuberculosis in Skopje. We measured the level of CRP in the blood in all of these patients in fasting conditions. The classification of COPD patients by the severity of airflow limitation was made according to the actual version of the Global initiative for chronic Obstructive Lung Disease (GOLD). The Student’s Independent Samples t-test was used for the statistic analysis of the data.
RESULTS: In 52 (65%) of the patients with exacerbation of COPD we detected an increase of the mean value of CRP. The statistical analysis using the Student’s t-test showed statistically significant differences in the mean value of CRP in patients with different level of bronchial obstruction. Hypertension, heart failure, diabetes mellitus, hyperlipidemia, coronary disease, and CVI were confirmed as co-morbidities in 45 (73.1%) of the patients, hypertension being the most frequent one (40%). The statistical analysis using the Student’s t-test showed statistically significant difference of the mean value of CRP (p< 0.01) depending on the number of co-morbidities.
CONCLUSION: In 52 (65%) of the patients with exacerbation of COPD, were detected an increase of the mean value of CRP. The mean values of CRP statistically significantly correlate with the level of bronchial obstruction and the number of co-morbidities in patients with COPD.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Lopez AD, Shibya K, Rao C, Mathers CD, Hanell AL. Held LS, Schmid V, Buist S. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006; 27(2): 397-412. DOI: https://doi.org/10.1183/09031936.06.00025805
Rennard SI. Inflammation in COPD: a link to systemic co-morbidities. Eur Resp Rev. 2007; 16(105): 91-97. DOI: https://doi.org/10.1183/09059180.00010502
Gin WQ, Min SFR, Senthiselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systemic review and a meta-analysis. Thorax. 2004;59, 574-580. DOI: https://doi.org/10.1136/thx.2003.019588
Barnes PJ. Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med. 2010;7(3):e1000220. DOI: https://doi.org/10.1371/journal.pmed.1000220
Murali Mohan BV, Sen T, Ranganath R. Systemic manifestations of COPD. J Assoc Physicians India. 2012;60 Suppl:44-7.
Molen T. Co-morbidities of COPD in primary care: frequency, elation to COPD, and treatment consequences. Primary Care Respiratory Journal. 2010; 19( 4): 326-334. DOI: https://doi.org/10.4104/pcrj.2010.00053
Yanbaeva DG, Dentener MA, Spruit MA, Duistermaat MA, Kotz D, Passos V, Wouters FM. IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: case control study. BMC Medical Genetics. 2009; 10: 23. DOI: https://doi.org/10.1186/1471-2350-10-23
GOLD. Global Initiative for chronic Obstructive Lung Disease. Global strategy for diagnosis, management and prevention of chronic obstructive lung disease. Gold website, www.gold COPD.org 2013.
Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. Thorax. 2010;65(10):930-6. DOI: https://doi.org/10.1136/thx.2009.130260
Nillawar AN, Joshi KR, Patil SB, Bardapurkak JS. Evaluation of HS -CRP and Lipid Profile in COPD. Journal of Clinical and Diagnostic Research. 2013; 7(5): 801-803. DOI: https://doi.org/10.7860/JCDR/2013/5187.2943
Kamiska KB, Kaminski J, Gabryel BH, Braer B. Coexisting chronic diseases in COPD- cause of elevation level of C- reactive protein? European Respiratory Society, Annual Congress, Stockholm, 2007.
van Gestel YR, Hoeks SE, Sin DD, Stam H, Mertens FW, Bax JJ, van Domburg RT, Poldermans D. Beta-blockers and health-related quality of life in patients with peripheral arterial disease and COPD. Int J Chron Obstruct Pulmon Dis. 2009;4:177-83. DOI: https://doi.org/10.2147/COPD.S5511
Rutten FH, Vonken EJ, at al. Cardiovascular magnetic resonance imaging to identify left-sided chronic heart failure in stable patients with chronic obstructive pulmonary disease. Am Heart J. 2008; 156: 506-512. DOI: https://doi.org/10.1016/j.ahj.2008.04.021
Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007;370(9589):797-9. DOI: https://doi.org/10.1016/S0140-6736(07)61383-X
Sidney S, SorelM, Quesenberry CP Jr, et al. COPD and incident cardiovascular disease hospitalization and mortality: Kaiser Permanente Medical Care Program. Chest. 2005; 128:2068-2075. DOI: https://doi.org/10.1378/chest.128.4.2068
Mapel DW, Hurley JS, Forest FJ, et al. Health care utilization in chronic obstructive pulmonary disease: aces-control study in health maintenance organization. Arch Intern Med. 2000; 160:2653-2658. DOI: https://doi.org/10.1001/archinte.160.17.2653
Walsh JW, Thomashow BM. COPD and co-morbidites; results of COPD Fondation national survey. Paper presented at: COPD and co-morbidites: treatinh the whole patient. ATS 2006 San Diego International Conference; 19-24; San Diego: CA, 2006.
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
